Apparently it looks like a simple tea bag but in reality it’s a genetically engineered concentrate able to completely revolutionize treatments for stroke patients. A special little bag called ‘CellBeads’ contains tiny capsules, each containing about 1 million stem cells. Thanks to genetic engineering techniques, stem cells taken from the bone marrow are transformed into a drug that protects brain cells from dying. This allows the cells to be rejuvenated and repair damage caused by the stroke. The stem cells are encapsulated to ‘fool’ the immune system, avoiding a rejection by the body. ‘CellBeads’ were developed by
Image via Wikipedia
The first patient in the landmark Pilot Investigation of Stem Cells in Stroke (PISCES) trial has been treated with neural stem cells. The study is the first fully regulated clinical trial of neural stem cell therapy for stroke. Investigators will evaluate the safety of ReNeuron cells in disabled ischemic stroke patients.
“This is a first in man safety study,” lead investigator Keith Muir, MD, from the University of Glasgow‘s Institute of Neuroscience and Psychology in Scotland, explained to Medscape Medical News. “We are looking at neurological effects — clinical and imaging — only as secondary goals.”
The stem cells
Stem Cell Therapeutics Corp. or the wishes to announce the acceptance and publication of the paper entitled “The Beta-hCG + Erythropoietin in Acute Stroke (BETAS) Study” by the journal “Stroke”, on March 8, 2010.
This paper was authored by Dr. Steven C. Cramer, from the University of California, Irvine, Dr. David Brown at Hoag Memorial Hospital Presbyterian, New Port Beach, Dr. Michael D. Hill of Foothills Hospital at the University of Calgary, and colleagues.
Dr. Allen Davidoff, VP of Product Development, commented as follows:
“The Stroke journal, published by the American Heart Association, is the top journal in the field of stroke
In a couple of months, the first test to verify if embryonic stem cells directly injected inside patients’ brain plagued by stroke can regenerate damaged areas, will start in Scotland.
A team from Southern General Hospital of Glasgow selected 4 groups of 3 patients that will be treated during the next 2 years.
Firstly patients will take a dose of 2 millions embryonic stem cells. The amount will be gradually increased to 20 millions of stem cells, which is what doctors think patients need to start the re-creating processes.
Progress has been made against strokes thanks to stem cells. British researchers, thanks to these cells, have managed to repair brain tissue damaged by a stroke. The study, financed by the research council on biological and biotechnological sciences of the United Kingdom, was published in Nature Biomaterials. The team from the Institute of Psychiatry at the University of Nottingham, used a biodegradable polymer called Plga to build a scaffold for neural cells.
Using these they filled the cavity left by a stroke. This allows, explained Mike Modo, psychiatrist at King’s College in London and coordinator of